$46.67
0.09% yesterday
Nasdaq, Jun 02, 10:15 pm CET
ISIN
US85205L1070
Symbol
SWTX
Sector
Industry

SpringWorks Therapeutics Inc Target price 2025 - Analyst rating & recommendation

SpringWorks Therapeutics Inc Classifications & Recommendation:

Hold
100%

SpringWorks Therapeutics Inc Price Target

Target Price $47.00
Price $46.67
Potential
Number of Estimates 6
6 Analysts have issued a price target SpringWorks Therapeutics Inc 2026 . The average SpringWorks Therapeutics Inc target price is $47.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 0 Analysts recommend SpringWorks Therapeutics Inc to buy, 6 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the SpringWorks Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the SpringWorks Therapeutics Inc stock at Hold.

Sales and Margin forecast 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 191.59 335.06
3,415.41% 74.88%
EBITDA Margin -143.36% -53.68%
97.71% 62.56%
Net Margin -134.73% -61.54%
97.74% 54.32%

7 Analysts have issued a sales forecast SpringWorks Therapeutics Inc 2025 . The average SpringWorks Therapeutics Inc sales estimate is

$335m
Unlock
. This is
52.53% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$398m 81.01%
Unlock
, the lowest is
$293m 33.15%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $192m 3,415.41%
2025
$335m 74.88%
Unlock
2026
$612m 82.75%
Unlock
2027
$839m 37.05%
Unlock
2028
$894m 6.48%
Unlock

2 Analysts have issued an SpringWorks Therapeutics Inc EBITDA forecast 2025. The average SpringWorks Therapeutics Inc EBITDA estimate is

$-180m
Unlock
. This is
31.06% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-164m 36.98%
Unlock
, the lowest is
$-195m 25.14%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-275m 19.54%
2025
$-180m 34.51%
Unlock
2026
$9.1m 105.03%
Unlock

EBITDA Margin

2024 -143.36% 97.71%
2025
-53.68% 62.56%
Unlock
2026
1.48% 102.76%
Unlock

8 SpringWorks Therapeutics Inc Analysts have issued a net profit forecast 2025. The average SpringWorks Therapeutics Inc net profit estimate is

$-206m
Unlock
. This is
18.80% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-113m 55.41%
Unlock
, the lowest is
$-312m 22.85%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-258m 20.60%
2025
$-206m 20.12%
Unlock
2026
$-61.9m 69.98%
Unlock
2027
$129m 308.77%
Unlock
2028
$292m 126.31%
Unlock

Net Margin

2024 -134.73% 97.74%
2025
-61.54% 54.32%
Unlock
2026
-10.11% 83.57%
Unlock
2027
15.40% 252.32%
Unlock
2028
32.73% 112.53%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.48 -2.75
32.43% 20.98%
P/E negative
EV/Sales 9.64

8 Analysts have issued a SpringWorks Therapeutics Inc forecast for earnings per share. The average SpringWorks Therapeutics Inc EPS is

$-2.75
Unlock
. This is
19.35% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.51 55.72%
Unlock
, the lowest is
$-4.16 21.99%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.48 32.43%
2025
$-2.75 20.98%
Unlock
2026
$-0.83 69.82%
Unlock
2027
$1.72 307.23%
Unlock
2028
$3.90 126.74%
Unlock

P/E ratio

Current -13.69 51.52%
2025
-16.97 23.99%
Unlock
2026
-56.54 233.18%
Unlock
2027
27.08 147.90%
Unlock
2028
11.97 55.80%
Unlock

Based on analysts' sales estimates for 2025, the SpringWorks Therapeutics Inc stock is valued at an EV/Sales of

and an P/S ratio of
10.50
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 14.70 85.24%
2025
9.64 34.45%
Unlock
2026
5.27 45.28%
Unlock
2027
3.85 27.03%
Unlock
2028
3.61 6.09%
Unlock

P/S ratio

Current 16.01 86.22%
2025
10.50 34.44%
Unlock
2026
5.74 45.28%
Unlock
2027
4.19 27.03%
Unlock
2028
3.94 6.09%
Unlock

Current SpringWorks Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Guggenheim
Locked
Locked
Locked May 12 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 30 2025
Guggenheim
Locked
Locked
Locked Apr 29 2025
TD Cowen
Locked
Locked
Locked Apr 29 2025
Barclays
Locked
Locked
Locked Apr 28 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 24 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 21 2025
Analyst Rating Date
Locked
Guggenheim:
Locked
Locked
May 12 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 30 2025
Locked
Guggenheim:
Locked
Locked
Apr 29 2025
Locked
TD Cowen:
Locked
Locked
Apr 29 2025
Locked
Barclays:
Locked
Locked
Apr 28 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 24 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 21 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today